FibroGen (FGEN) Misses Q4 EPS by 79c

FibroGen (NASDAQ: FGEN) reported Q4 EPS of ($1.45), $0.79 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $16.5 million versus the consensus estimate of $47.65 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
• LiqTech International (LIQT) Reports In-Line Q2 EPS